Patient's Assessment of Gout Pain Intensity in the Currently Most-affected Joint (Likert Scale);Patient's Global Assessment of Response to Treatment for Patients Re-treated or Switched to Canakinumab;Physician's Assessment of Joint Tenderness for Patients Re-treated or Switched to Canakinumab;Physician's Assessment of Joint Swelling for Patients Re-treated or Switched to Canakinumab;Physician's Assessment of Erythema for Patients Re-treated or Switched to Canakinumab;Physician's Global Assessment of Response to Treatment for Patients Re-treated or Switched to Canakinumab;Serum Amyloid A Protein (SAA) Levels for Patients Re-treated With or Switched to Canakinumab;High-sensitivity C-reactive Protein (hsCRP) Levels for Patients Re-treated With or Switched to Canakinumab;Flare Rate Per Year;Time to First New Flare: Survival Analysis by Treatment (72 Weeks Overall);Patient's Assessment of Gout Pain Intensity in the Most Affected Joint (Likert Scale);Physician's Assessment of Range of Motion of the Most Affected Joint;Physician's Assessment of Tenderness, Swelling, and Erythema of the Most Affected Joint;Patient's Global Assessment of Response to Treatment;Physician's Global Assessment of Response to Treatment;High-sensitivity C-reactive Protein (hsCRP) and Serum Amyloid A Protein (SAA) Levels for Core and 24 Weeks Overall;Percentage of Participants Who Took Rescue Medication;Amount of Rescue Medication Taken;Percentage of Participants With Maximum Severity of Last Post-baseline Flare (5-point Likert Scale);Patient's Assessment of Gout Pain Intensity in the Most Affected Joint on a Visual Analog Scale (VAS) in Extension;Time to First Intake of Rescue Medication After the Last Post Baseline Flare.;Mean Number of New Gout Flares Per Patient During the 24 Weeks of the Study;Time to First New Flare;SF36 Physical Function Score at Week 12;Mean Number of New Gout Flares Per Patient;Percentage of Participants With at Least 1 New Gout Flare During the 12 Weeks;Percentage of Participants With Complete Resolution of Pain;Time to Complete Resolution of Pain;Time to at Least a 50% Reduction in Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (0-100mm VAS)